From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Values in DS patients compared to controls | Values in dDS compared to cnDS | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Study | Subjects | Mean age (years) | Platform and antibodies | %CV | Aβ1-40 | Aβ1-42 | Aβ1-42/Aβ1-40 | Aβ1-40 | Aβ1-42 | Aβ1-42/Aβ1-40 | |
Schupf et al. 2001 [52] | 97 cnDS | 51.9 | ELISA | - | ↑ | ↑ | - | = | ↑ | - | |
11 dDS | 56 | 6E10 | |||||||||
R182 | |||||||||||
R165 | |||||||||||
Schupf et al. 2007 [32] | ELISA | - | - | - | - | = | ↑ | - | |||
6E10 | |||||||||||
R182 | |||||||||||
R165 | |||||||||||
Matsuoka et al. 2009 [53] | 148 cnDS | 54.2 | ELISA | <11.0% | - | - | - | = | = | ↑ | |
52 dDS | 56.0 | 82E1 | |||||||||
1A10 | |||||||||||
1C3 | |||||||||||
Prasher et al. 2010 [35] | 83 cnDS | 49.0 | ELISA | - | - | - | - = | = = | a | ||
52dDS | 56.8 | 6E10 | |||||||||
R182 | |||||||||||
R165 | |||||||||||
Head et al. 2011 [34] | 11 yCN | 46.5 | ELISA | - | ↑ | ↑ | = | - | - | - | |
12 aCN | 74.2 | Wako | |||||||||
17 AD | 75.3 | ||||||||||
43 cnDS | 45 | ||||||||||
52 dDS | 53.3 | ||||||||||
Coppus et al. 2012 [54] | 62 dDS | 54 | xMAP | - | - | - | - | ↑ | = | = | |
264 cnDS | 50.6 | INNO-BIA | |||||||||
Reiman et al. 2012 [51] | 10 PSEN1+ CN | 23 | xMAP | - | - | - | - | - | - | - | |
10 PSEN1- CN | 24 | INNO-BIA |